Novartis Sustainability Profile
Novartis AG, a leading global healthcare company headquartered in Switzerland (CH), has established itself as a pioneer in the pharmaceutical industry since its founding in 1996. With a strong presence in key operational regions including North America, Europe, and Asia, Novartis focuses on innovative medicines, generics, and eye care products. The company is renowned for its commitment to research and development, producing unique therapies in areas such as oncology, cardiology, and immunology. Notable achievements include the development of groundbreaking treatments that have transformed patient care. As a top player in the pharmaceutical market, Novartis continues to drive advancements in healthcare, making significant contributions to global health and well-being.
DitchCarbon Score
How does Novartis's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novartis's score of 100 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novartis's reported carbon emissions
In 2024, Novartis reported total carbon emissions of approximately 4,587,300,000 kg CO2e, with Scope 1 emissions at about 207,000,000 kg CO2e, Scope 2 emissions at approximately 30,000,000 kg CO2e (market-based), and a significant Scope 3 contribution of around 4,350,300,000 kg CO2e. This reflects a reduction from 2023, where total emissions were about 4,868,900,000 kg CO2e, with Scope 1 at 251,100,000 kg CO2e and Scope 2 at approximately 44,100,000 kg CO2e (market-based). Novartis has set ambitious climate commitments, aiming for carbon neutrality in its own operations (Scope 1 and 2) by 2025. The company has also pledged to achieve net-zero emissions across its entire value chain by 2040. Specifically, Novartis targets a 90% reduction in absolute Scope 1 and 2 emissions and a 42% reduction in absolute Scope 3 emissions by 2030, using 2022 as the baseline year. These targets are aligned with the Science Based Targets initiative (SBTi) and are consistent with the goal of limiting global temperature rise to 1.5°C. In recent years, Novartis has made significant progress, reducing its Scope 1 and 2 emissions by 19% year-on-year, amounting to a total reduction of 63% compared to its 2016 baseline. The company is committed to including environmental criteria in all supplier contracts by 2025, further enhancing its sustainability efforts. Overall, Novartis's climate strategy reflects a strong commitment to reducing its carbon footprint and contributing to global climate goals, with a focus on both immediate and long-term sustainability initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 922,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Novartis's Industry?
How Carbon Intensive is Novartis's Location?
Novartis's Scope 3 Categories Breakdown
Novartis's Scope 3 emissions, which decreased by 5% last year and increased significantly since 2013, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 78% of Scope 3 emissions.
Top Scope 3 Categories
Novartis's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Novartis has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
GlaxoSmithKline Pakistan Limited
Frequently Asked Questions
Common questions about Novartis's sustainability data and climate commitments